🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the fight against superbug strains of the pathogen, according to health experts.

A Worldwide Challenge

Cases of gonorrhoea are on the rise around the world, with estimates suggesting more than 82 million infections annually. Especially elevated rates are observed in Africa and nations within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. In England, cases have hit a record high, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an important and timely advancement in the reality of rising global incidence, increasing antimicrobial resistance and the highly restricted therapeutic options currently available.”

Health officials are deeply concerned about the rise in antibiotic-resistant strains. The World Health Organization has classified it as a "high-priority threat". Ongoing monitoring revealed that the effectiveness of primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Therapies Receive Clearance

Zoliflodacin, marketed under the name Nuzolvence, was cleared by the US FDA in December for use against gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Experts hope that focused deployment of this new drug will help slow the emergence of superbugs.

Gepotidacin, created by the drugmaker GSK, was also approved in the same week. This treatment, which is employed against UTIs, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin emerged from a innovative non-profit model for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to bring it to fruition.

“This approval marks a huge turning point in the management of multidrug-resistant gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Testing Data and Global Access

As per findings detailed in a prominent scientific publication, zoliflodacin cured the vast majority of cases of the STI. This establishes an equal footing with the current standard treatment, which combines two antibiotics. The research included over 900 participants from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, the non-profit has the rights to register and commercialise the drug in numerous low-income and middle-income countries.

Clinicians treating patients have voiced optimism. The availability of a one-pill regimen like this is seen as a "revolutionary step" for public health efforts. This is considered essential to alleviate the strain of the infection for individuals and to stop the proliferation of untreatable gonorrhoea worldwide.